Shawn has held various leadership positions; CEO, senior executive, and board member. Shawn has co-founded multiple medical device companies with several successful exists: EP Dynamics, Lavita Technologies, Renal Dynamics, Vessix Vascular, Ellipse Technologies, Savona Therapeutics, and Oncogenics Guidance Systems. Shawn is also founder & chairman of Adventus Ventures, chairman of the board at Anaxiom Corp, chairman of the board at Pressao Medical, and chairman of the board at Vascular Health.

Mr. Werneth is CEO of Maxwell Biomedical, Inc. developing the next generation of wireless remote cardiac pacing and monitoring implantable device. Mr. Werneth is partner at Evolve Medtech Partners, a technology development company. Previously, Mr. Werneth successfully started several other venture backed companies including Acutus Medical, Securus Medical, Ablation Frontiers, and CryoTherapeutics. Mr. Werneth previously held senior level positions at Medtronic, Micro Therapeutics, and Edwards Lifesciences where he engineered and/or managed the design and development of numerous medical technologies and clinical procedures in the fields of stents, neuro-embolic materials, vulnerable plaque, and electrophysiology. He also sits on the board of several venture funded medical device companies in the US and Europe. Mr. Werneth holds a B.S. degree in Engineering from Arizona State University (ASU) and a Masters in Science from University of California at Los Angeles (UCLA). He has more than 70 issued U.S. Patents in various medical technology fields.

Shinya is currently CEO & President of Neuroceuticals, Inc., a privately held company supporting overseas start-up medical device companies entering the Japanese market by investing, and setting up marketing strategy in Japan including obtaining government approval (PMDA approval).

He has also served on the boards of Volcano Corporation, a company that develops intravascular ultrasound that aid in the diagnosis and treatment of vascular and structural heart disease. TomoTherapy Incorporated, an advanced radiation therapy company that markets systems for the treatment of a wide range of cancer types. And Coherex, an atrial appendage closure device company. Prior to his retirement, Roy was the Worldwide President of Biosense Webster, a Johnson & Johnson Company, from March, 2004 until his retirement in September, 2008. Biosense Webster is the market and technology leader in the field of electrophysiology, a subspecialty of cardiology dedicated to the diagnosis and treatment of heart rhythm disorders.

He is a cofounder of Highpoint Therapeutics, an oncology startup focused on killing cancer stem cells with nanoencapsulated salinomycin and other agents. A graduate of the University of Southern California (USC) School of Medicine, James received residency training in internal medicine and in radiology at the Massachusetts General Hospital and Harvard Medical School, where he was awarded a fellowship in neuroradiology. He completed coursework in the Master of Science in Electrical Engineering program at USC, with an emphasis in signal and image processing. He is a member of the American Society for Clinical Nutrition with a research interest in Alzheimer’s disease and other neurodegenerative diseases. James is recommended in Chambers USA and The Legal 500 United States in the area of life sciences and named a leading patent professional in California by IAM Patent 1000 – The World’s Leading Patent Practitioners for both patent litigation and prosecution, and a Top 25 Portfolio Manager by the Daily Journal. He has served on the scientific board of advisors for several life science companies.

He has been on the academic faculties of UCLA and Stanford University Medical Schools and is now the Director of Department of Clnical Trials at St Joseph Heart & Vascular Center. To date, he has authored or co-authored over 300 scientific publications, abstracts, and book chapters and has been the recipient of many honors and awards from multiple professional medical societies. He has been the recipient of several industry, institutional and federal grants and has given over 450 invited lectures in National & International scientific meetings. Dr. Razavi has served as the Editor and on the Editorial Boards of several scientific journals. His scientific work has been featured in over 100 national & international radio, television, and press news articles and programs. Dr. Razavi is the co-founder of four medical device companies with a total exit valuation of over $600M including Trivascular and Neuravi and has served on the Board of Directors and the Scientific and Strategic Advisory Boards of over 40 device and biotechnology companies.

Dr. Wang currently is chairman of the board of HeMo Bioengineering Limited, medical device company established in 2017 primarily focused on neurovascular intervention currently in China with two operating institutions, Weihai R&D and production and Beijing marketing and sales headquarters. Prior to this. Dr. Wang was CEO of Biosensors International, responsible for significant growth and strategic direction leading to the acquisition of several successful companies. Prior to joining Biosensors in 2001, Dr. Wang had worked for Johnson & Johnson (Cordis) and Guidant Corporation. Dr. Wang was granted more than 20 US and European patents in medical devices and technology and has published more than 30 scientific papers on polymer materials and processing according to a Biosensors International Group report. Dr. Wang received his doctorate in polymer science from Case Western Reserve University, Cleveland.

Shigeru is currently board of Medical Development Support 1 Limited Partnership with over 20 years of VC investment experience with Mitsubishi UFJ Capital. Shigeru has been involved with multiple successful exits with both Japanese and U.S. companies including Five Prime Therapeutics, Inc.(FPRX), Opko Health ,Inc.(OPK), Affymax,Inc.(AFFY), MacroGenics Inc. (MGNX), KaloBios Pharmaceuticals,Inc (KBIO), iPierian Inc.,(Acquired by Bristol Myers Squibb), Solasia Pharmaceuticals (Tokyo Stock Exchange, Mothers), SanBio (TSE, Mothers), StemRim (TSE ,Mothers), and Modaris (TSE ,Mothers). Shigeru was previously a board member of TMS,Co., Ltd., developing a novel acute stroke agent and was acquired by Biogen in June 2021.

Professor of Neurology, Director, Movement Disorders Program, University of California, Irvine 1999-2020; Section Lead, Neurology, CHRISTUS-St. Vincent Regional Medical Center, Santa Fe, NM 2020-2022.

Prior to joining Allevion Therapeutics, Nick was the director of technology and innovation at PKG User Interface, Inc., responsible for all aspects of system design for medical, aviation, and industrial customers. Nick holds a Master of Science in Engineering from Boise State University.